Generare raises $23.2M to discover unknown molecules and advance new drugs

Generare Bioscience SAS's raise of $23.2 million to discover unknown molecules and advance new drugs using artificial intelligence marks a significant investment in the biotechnology sector. This development is particularly relevant for website owners in the pharmaceutical and biotechnology industries, as it highlights the growing importance of AI in drug development and molecular research. As AI-generated content becomes more prevalent in these fields, website owners may see an increase in AI bot traffic to their sites, particularly from researchers and scientists seeking information on new molecules and drug discoveries. To prepare for this potential surge in AI bot traffic, website owners can take several actionable steps: firstly, review and update their llms.txt files to ensure they are accurately tracking and managing AI bot interactions; secondly, consider implementing AI-specific content policies to address the potential for AI-generated content on their sites; and thirdly, monitor their website analytics to identify and understand the sources and patterns of AI bot traffic, allowing them to optimize their content and user experience accordingly.